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Comparison of Target Lesion and Vessel Revascularization in Women of
Different Age Groups after Percutaneous Coronary Intervention for Acute
Coronary Syndrome
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Ron Waksman4
1Washington Hospital Center/Georgetown University Hospital, Washington, DC,
2Washington Hospital Center, washington, DC, 3Washington Hospital Center,
Washington, DC, 4Georgetown University, Washington, DC
Background: Women have a lower risk for coronary artery disease (CAD) and present
at an older age with multiple comorbidities. Young women who present with CAD, albeit
uncommon, likely reflect accelerated progression of atherosclerosis. It is unclear whether
presentation of CAD in women younger than 55 translates into higher rates of target lesion
revascularization (TLR) and target vessel revascularization (TVR) post percutaneous
coronary intervention (PCI). We compared rates of TLR and TVR at 1 year post PCI in
women younger and older than 55.
Methods: 2219 women who underwent PCI at Washington Hospital center for an acute
coronary syndrome were divided by age into four groups (less than 35: 14 patients, 35-45:
83 patients, 45-55: 295 patients, and older than 55: 1827 patients). TLR and TVR were
recorded at 1 year (2030 and 2044 patients respectively).
Results: There were no significant difference in the use of stents, use of drug eluting
stents (DES), stent number, length or diameter in the different age groups. There were no
differences in post PCI care with anti-platelet and statin therapy. Rates of TLR and TVR
were significantly different among the various age groups with higher rates in younger
groups:
Conclusions: Despite comparable rates of stent use, including DES, and comparable post
PCI medical management, women in the younger age groups had higher rates of TLR and
TVR at 1 year post PCI. Coronary artery disease in younger women likely reflects a more
accelerated progression of the disease warranting close follow up.
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Background: Drug-eluting stents (DES) for the treatment of unprotected left main
coronary artery (ULMCA) disease have been shown to be safe and effective. The aim was
to assess clinical outcomes according to sex in this subset of patients.
Methods: All consecutive patients from our single-center prospective registry treated for
ULMCA stenosis with both first- and new-generation DES from January 2005-June 2010
were analyzed. The study objectives were all-cause mortality, major adverse cardiac
events (MACE), target vessel revascularization (TVR) and target lesion revascularization
(TLR) at 2-years clinical follow-up.
Results: A total of 173 patients were included in the analysis. Notably, only 17.9% were
females. No differences were observed between genders in baseline clinical characteris-
tics. Regarding lesion characteristics, males were more likely to have distal ULMCA
lesions affecting the bifurcation (83.8% vs. 61.3%; p0.005) and undergo a 2-stent
strategy (50.4% vs. 25.8%; p0.013). In addition, males were significantly more likely to
undergo paclitaxel-eluting stent implantation (34.5% vs. 9.7%; p0.006). At 2-years
clinical follow-up, there was a trend for increased all-cause mortality in females (12.9%
vs. 4.2% vs. p0.061). Conversely, there were no significant differences in TLR between
females and males respectively (6.5% vs. 6.3%; p0.981), TVR (22.6% vs. 14.1%;
p0.238), MI (3.2% vs. 1.4%; 0.483), MACE (29.0% vs. 16.9%; p0.119). Moreover,
there were 4 definite/probable stent thrombosis, all in first-generation DES, however this
was not affected by the sex of the patient (3.2% vs. 2.1%; p0.709).
Conclusions: Treatment with DES for ULMCA appears safe and effective regardless of
sex. Despite more distal bifurcation lesions amongst males, there was a trend for a higher
all-cause mortality amongst females which clearly needs to be assessed with larger patient
numbers.
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Background: Right Ventricular Failure (RVF) is a clinical problem associated with a
high mortality that occurs in a variety of settings including post-cardiotomy cardiogenic
shock, cardiac transplant, right ventricular infarction, pulmonary embolism and after left
ventricular assist device (LVAD) implantation. Temporary mechanical right ventricular
support could be a reasonable alternative treatment option in these patients. We report
here the initial first clinical evaluation of a novel minimally invasive percutaneous right
ventricular assist device.
Methods: Impella RP is a new, minimally invasive, 3D catheter-based percutaneous
microaxial pump that is designed for short-term right ventricular support. The device requires
single vascular access through a sheath in the femoral vein. The device (22 Fr pump mounted
on an 11 Fr catheter) is positioned under fluoroscopic guidance using a 0.025wire. It aspirates
blood from the inferior vena cava and expels it into the pulmonary artery at the maximum rate
of up to 4.4 liters per minute. The device requires low anticoagulation regimen.
Results: A First in Man pre-market clinical feasibility evaluation has been initiated at several
sites in Canada and Europe in patients experiencing right ventricular failure in different clinical
settings.Indications for use at the time of this submission included RVF post heart transplant
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(2), RVF post cardiac surgery (1), RVF post LVAD implantation (2) and RVF post acute
myocardial infarction (1). All patients were in cardiogenic shock prior to Impella RP
implant.The percutaneous implant of the device was feasible and successful in 100% of the
patients. The support time ranged from 1 to 9 days, with more than 60% of the patients being
supported for longer than 4 days (median of 6.5 days) and explanted upon RV recovery. The
average flow was 3.9 L/min. Overall thirty-day survival was 83%.
Conclusions: A novel percutaneous right ventricular assist device has been developed.
The design was enhanced after the first implant to improve torque-ability and push-ability
which resulted in an ease of placement for the subsequent patients. The preliminary
clinical experience is very encouraging and further evaluation is ongoing.
TCT-372
Coronary artery disease in patients with reduced left ventricular systolic
function treated with medicine, surgery, or percutaneous coronary
intervention: a retrospective review of outcomes within a multicenter
healthcare system
Matthew LaBarbera1, Peter Hui1, Richard Shaw1
1California Pacific Medical Center, San Francisco, CA
Background: Patients with multivessel coronary artery disease (CAD) and
reduced left ventricular ejection fraction (LVEF) are at risk for significant
morbidity and mortality. There is limited data comparing medical therapy,
coronary artery bypass graft surgery (CABG), and percutaneous coronary inter-
vention (PCI) in patients with CAD and LVEF 35%. The current study evaluates
the clinical characteristics and outcomes for patients with significant CAD and
reduced LVEF treated with medical therapy, CABG, or PCI.
Methods: A retrospective analysis was conducted on consecutive patients in the Sutter
Health System in Northern California without prior CABG who underwent coronary
angiography between 1/1/2003 and 12/31/2009 and were found to have LVEF35% and
significant CAD (left main stenosis 50% or greater, proximal LAD stenosis 70% or
greater, or 70% stenosis in 2 or more major epicardial vessels). Patients undergoing
emergent cardiac catheterization were excluded. A Cox proportional hazards regression
analysis was performed to compare medical therapy, CABG, and PCI for the outcome of
long-term survival, adjusting for baseline demographic and clinical characteristics. The
Social Security death index was used to assess long-term mortality.
Results: 1345 patients with CAD and reduced LVEF were identified: 498 had PCI, 493
had CABG, and 354 received medical therapy alone. Patients receiving medical therapy
alone were more likely to be female, have a history of myocardial infarction, and have a
history of heart failure (p0.001). In-hospital mortality rates for the CABG, PCI, and
medical therapy groups were similar (6.7% vs. 5.4% vs. 9.0 %; p0.118). The 5-year
adjusted survival for the CABG, PCI, and medical therapy cohorts was 76%, 65%, and
52%, respectively (p0.0001).
Conclusions: In a large hospital network, patients with CAD and reduced LVEF had
improved long-term mortality when treated with revascularization (CABG or PCI) compared
with medical therapy alone. Notably, patients with CAD and reduced LVEF had improved
long-term mortality when treated with PCI compared with medical therapy. Further studies are
warranted regarding the optimal treatment for patients with CAD and reduced LVEF.
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Impact of Epicardial Fat Volume on Coronary Artery Disease in Symptomatic
Patients with a Zero Calcium Score
Tsuyoshi Ito1, Mitsuyasu Terashima1, Kenya Nasu1, Masashi Kimura1,
Yoshihisa Kinoshita1, Yasushi Asakura1, Etsuo Tsuchikane1, Takahiko Suzuki1
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Background: Prevalence of coronary artery disease (CAD) is not fully elucidated in
symptomatic patients with a zero calcium score (CS) by computed tomography (CT).
Epicardial fat volume (EFV) has been suggested as a predictor of CAD. The aim of our
study is to investigate the prevalance of CAD and the impact of EFV on CAD in
symptomatic patients with a zero CS with multislice CT (MSCT).
Methods: In this study, 1308 consecutive symptomatic patients who underwent 64-slice
MSCT with a zero CS were evaluated. EFV was quantified with CS data sets. Presence
of an obstructive plaque (diameter stenosis50%) and a CT-derived vulnerable plaque,
which was defined as a plaque with remodeling index1.10 and mean CT density value
30Hounsfield Units, was assessed with a CT coronary angiography.
Results: Obstructive plaques were detected in 86 patients (7%) and CT-derived
vulnerable plaques in 63 (5%). EFV was larger in patients with obstructive plaques than
no plaque (124.343.2cm3 vs. 95.140.3cm3; p0.01). Patients with CT-derived
vulnerable plaques had a greater amount of EFV than no plaque (133.040.2cm3 vs.
95.140.3cm3; p0.01). Multivariate analysis revealed EFV as a predictor of the
presence of an obstructive and a CT-derived vulnerable plaque (per 10cm3; Odds ratio
(OR) 1.10; 95% confidence interval (CI), 1.04-1.16; p0.01 and OR 1.19; 95% CI,
1.12-1.27; p0.01). The combination of EFV and Framingham risk score (FRS) resulted
in an area under the receiver-operating characteristic curve for prediction of obstructive
and CT-derived vulnerable plaque of 0.75 and 0.75, which was significantly higher than
0.68 and 0.64 for FRS alone (p 0.02 and p0.01).
Conclusions: A zero CS doesn’t exclude CAD and EFV can be a useful marker of CAD
in symptomatic zero CS patients.
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Long-term Survival and Neurological Outcome of In-hospital Cardiac Arrest
Patients Rescued by Extracorporeal Cardiopulmonary Resuscitation
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Background: The immediate clinical benefit of extracorporeal cardiopulmonary resus-
citation (E-CPR) has been proved in short-term follow-up studies. However, it has been
not known whether the benefit of E-CPR persists for more than 1 year. We compared the
long-term outcomes of patients who received E-CPR or conventional CPR (C-CPR) and
investigated the clinical characteristics of long-term survivors.
Methods: We analyzed a total of 406 adult in-hospital cardiac arrest victims received
CPR for more than 10 minutes from 2003 to 2009. The long-term survival and
neurological outcome of E-CPR (n85) and C-CPR (n321) were compared using
propensity score-matched analysis.
Results: The 2-year survival with minimal neurological impairment was 4-fold higher in
E-CPR group than C-CPR group (23.5% versus 5.9%, hazard ratio (HR)  0.57, 95%
confidence interval (CI)  0.43–0.75, p0.001) by unadjusted analysis. After propensity-
score matching, it was still 4-fold higher in E-CPR group than C-CPR group (20.0% versus
5.0%, HR0.53, 95% CI0.36–0.80, p0.002). In the E-CPR group, the independent
predictors associated with minimal neurological impairment were age65 years (HR0.46;
95% CI0.26–0.81; p0.008), CPR duration 35 min (HR0.37; 95% CI0.18–0.76;
p0.007), and subsequent cardiovascular intervention including coronary intervention or
cardiac surgery (HR0.36; 95% CI0.18–0.68; p0.002).
Conclusions: The initial survival benefit of E-CPR for cardiac arrest patients was
maintained at 2 year.
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Optimizing Rotational Atherectomy in High-Risk Percutaneous Coronary
Interventions. Insights from the PROTECT  study
Mauricio Cohen1, Abhijit Ghatak1, Neal Kleiman2, Srihari Naidu3,
E. Magnus Ohman4, Igor Palacios5, Alan Heldman1, William O’Neill1
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Background: Rotational Atherectomy (RA) is currently recommended for heavily
calcified lesions in which standard percutaneous coronary intervention (PCI) techniques
would result in suboptimal stent expansion. We sought to determine the optimal RA use
associated with minimal incidence of myonecrosis in patients undergoing high-risk PCI
supported by either intraaortic balloon (IABP) or microaxial flow pumps (Impella).
Methods: We performed a subgroup analysis of patients treated with RA in the
PROTECT  trial. The objective was to examine the relationship between myonecrosis
and the technical parameters burr size, number of passes/patient/lesion, and RA time.
Peri-procedural myocardial infarction (MI) was defined in the study as increase of
CK-MB or Troponin 3xULN. Continuous variables were expressed as means SD. A
P value 0.05 was considered significant.
Results: RA was used in 52 patients of the 448 PROTECT II patients (11.6%).
Compared to patients treated without RA, patients undergoing RA were older (72
vs. 67 yo, p0.001), were more likely to have heart failure (96% vs. 86%,
p0.04), prior CABG (48 vs. 32%, p0.02), higher STS score (8.1 vs. 5.7,
p0.04), and higher Syntax score (40 vs. 29, p0.0001). Myonecrosis occurred
in 25% of RA cases. Of note, lesion length was similar in patients with and
without myonecrosis (39 vs. 38 mm, p0.96). Prolonged RA time was associated
with increased incidence of periprocedural myonecrosis (Table).
Variable MI (n12) No MI (n40) p value
Burr size (mm) 1.70.25 1.6 0.2 0.18
Number of passes/lesion 3.0 1.7 2.7 1.9 0.36
Number of passes/patient 6.4 3.6 4.7 3.8 0.15
RA time (seconds) 85.9 53.8 55.3 47.2 0.03
Conclusions: RA continues to be utilized in high-risk PCI procedures. Our study
suggests that longer RA time is associated with myonecrosis in patients undergoing
high-risk PCI. Optimal RA technique must balance the risk of myonecrosis against the
imperative to achieve a good luminal result.
TCT-376
SIMPLIPHieDE Study - Single center IMPella LVAD supported Pci in High Risk
group of patients – Detroit Medical Center Experience – Clinical Outcomes
Haroon Faraz1, Tamam Mohamad1, Rohit Amin1, Hassan Ismail1,
Obrad Kokanovic1, Antwon Robinson1, Sabeeh Siddiqui1, Muhammad Shahzad1,
Theodore Schreiber1
1Detroit Medical Center Cardiovascular Institute Wayne State University, Detroit, MI
Background: Advances in percutaneous interventional techniques and technology have
made percutaneous coronary intervention (PCI) for left main and or triple vessel disease
a viable option. Left main intervention was re-classified in the recent ACC guidelines
from III to IIb based on the large randomized Syntax trial. Though patients with high
syntax score still continue to benefit from CABG, in real-world clinical practice patients
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